HMGB1 and breast cancer: The therapeutic relevance of this immunogenic axis is particularly evident in breast cancer, where neoadjuvant chemotherapy agents induce GSDME-mediated pyroptosis accompanied by HMGB1 release, resulting in enhanced phagocytosis by macrophages and increased secretion of IFN-γ and IL-2 [192].